MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 85 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,233,378 | +24.4% | 650,109 | +67.8% | 0.00% | 0.0% |
| Q2 2023 | $4,208,380 | +135.9% | 387,512 | +49.9% | 0.00% | – |
| Q1 2023 | $1,783,705 | +5.8% | 258,508 | -39.0% | 0.00% | – |
| Q4 2022 | $1,685,443 | -13.1% | 423,478 | +45.1% | 0.00% | – |
| Q3 2022 | $1,939,000 | +42.2% | 291,753 | +3.5% | 0.00% | – |
| Q2 2022 | $1,364,000 | -6.4% | 281,865 | +80.8% | 0.00% | – |
| Q1 2022 | $1,458,000 | -69.6% | 155,925 | -61.4% | 0.00% | -100.0% |
| Q4 2021 | $4,801,000 | +53.7% | 404,140 | +47.2% | 0.00% | – |
| Q3 2021 | $3,123,000 | -60.4% | 274,552 | -37.5% | 0.00% | -100.0% |
| Q2 2021 | $7,887,000 | +64.7% | 439,615 | +42.1% | 0.00% | +100.0% |
| Q1 2021 | $4,789,000 | +30.7% | 309,391 | +3.0% | 0.00% | 0.0% |
| Q4 2020 | $3,665,000 | +448.7% | 300,425 | +477.4% | 0.00% | – |
| Q3 2020 | $668,000 | – | 52,028 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |